Skip to main content

Day: September 16, 2025

Close-Up International Acquires Pharma CRM Provider MobileDotRep to Expand U.S. Presence and Compete with Veeva and Salesforce

PRINCETON, N.J., Sept. 16, 2025 (GLOBE NEWSWIRE) — Close-Up Intl, a global leader in AI-powered CRM market data and business intelligence solutions for the pharmaceutical industry, has announced it acquired MobileDotRep, a life sciences CRM solution provider based out of Thousand Oaks, CA. This acquisition is another milestone for Close-Up, who has been a pioneer in pharma CRM since 1994 and a 5-Star rated Pharma CRM provider on Gartner’s Peer Insights: https://www.gartner.com/reviews/market/crm-in-life-sciences “We are pleased to further expand our Global and US pharma CRM presence, especially with the separation of Veeva and Salesforce, which presents a tremendous opportunity for Close-Up to further expand our success converting CRM clients in the United States,” commented Robert Thomas, Chief Commercial Officer of Close-Up Intl....

Continue reading

DAVIDsTEA Stays the Course in the Second Quarter

Sales reached $11.1 million, up 0.5% year-over-year Gross profit margin attained 47.2%, down marginally by 0.1% Net loss remained stable at $1.6 million Adjusted EBITDA was negative $0.2 million compared to negative $0.3 million in Q2 2024 New stores earmarked for South Shore of Montreal, Quebec City and MississaugaMONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (TSX-Venture: DTEA) (“DAVIDsTEA” or the “Company”), a leading North American tea merchant, announced today its financial results for the second quarter of fiscal 2025 ended August 2, 2025. “DAVIDsTEA stayed the course with its omnichannel growth strategy in the second quarter of 2025, supported by retail store and wholesale channel sales increases of 9.1% and 2.5% year-over-year, respectively,” said Sarah Segal, Chief Executive Officer and Chief Brand Officer,...

Continue reading

Strive Announces Acquisition of MSTR True North Inc. Appoints Jeff Walton as Chief Risk Officer & CEO of True North

Dallas, TX, Sept. 16, 2025 (GLOBE NEWSWIRE) — Strive, Inc. announces a strategic acquisition of MSTR True North Inc. (True North) in a de minimis cash transaction. True North is cash flow positive and the transaction synergies are expected to allow enhanced platform expansion without additional cost. This move cements Strive’s position at the forefront of Bitcoin advocacy in the new frontier of Digital Capital and Digital Credit. As part of the acquisition, Strive has appointed True North founder Jeff Walton as Chief Executive Officer of True North and Chief Risk Officer of Strive.  True North member Ben Werkman will continue to serve on Strive’s board of directors. This transaction also marks a new expansionary era for the True North media platform, including its Investment Grade Bitcoin podcast and Bitcoin treasury thought leaders,...

Continue reading

Mirasol Advances Large Untested Target Towards Drilling at the Flagship Sobek Copper-Gold Project in the Vicuña District, Chile

Geochemical soil survey defined a large (~1.0 × 0.7 km), prominent and coherent copper-gold-moly anomaly where structurally controlled hydrothermal and tourmaline breccias breach the surface The 46 South target lies on the southern margin of a district scale (~6 x 6 km) circular magnetic high Ground-based IP responses and coincident cylindrical shaped magnetic susceptibility and MT anomalies directly underlie the soil anomaly and breccias on surface Ahead of the drill program we anticipate launching in early November, a Deep Vector IP and MT survey will be deployed to refine geometry and enhance vectoring of the targets The 46 South target is located just 7 km west of Filo del Sol at the southern end of a parallel 3 km corridor of mineralization Webcast video presentation highlighting the potential of the 46 South target is available...

Continue reading

Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme

Positive results show that the average weight loss was 12.5 kg (11.8% body weight reduction) with cagrilintide compared to 2.5 kg (2.3%) with placebo, after 68 weeks*1,2 Cagrilintide was well-tolerated, with the most common side effects being gastrointestinal; these were mainly transient and mild to moderate in severity1 Based on these results, Novo Nordisk will advance cagrilintide into the dedicated RENEW phase 3 clinical programme later this yearBagsværd, Denmark, 16 September 2025 – Novo Nordisk today presented data from a sub-analysis of the phase 3 REDEFINE 1 trial at the European Association for the Study of Diabetes (EASD) congress 2025 from 15–19 September in Vienna, Austria. This sub-analysis evaluated the efficacy and safety of once-weekly cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity...

Continue reading

Enerflex Ltd. Announces the Appointment of Paul Mahoney as President, CEO and Director

CALGARY, Alberta, Sept. 16, 2025 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today announced the appointment Paul E. Mahoney as the Company’s President and Chief Executive Officer, effective September 29, 2025. Mr. Mahoney will also join Enerflex’s Board of Directors at the same time. The appointment follows an extensive global search process, which included the evaluation of highly qualified internal and external candidates, and was aided with the support of a global executive search firm. Kevin Reinhart, Chair of the Board, stated, “We are pleased to welcome Paul as Enerflex’s new President and CEO. With over 30 years of experience across the industrial and energy sectors, Paul is a highly accomplished and seasoned executive. His broad industry experience, proven track record of...

Continue reading

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

Posters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces two posters on additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”), will be presented at the European Respiratory Society (“ERS”) International Congress 2025. The abstracts are available to conference participants on the ERS website and will be published in an upcoming issue of the peer reviewed publication, European Respiratory Journal. Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the...

Continue reading

Volatus Aerospace Secures Major Multi-Year Agreement with a Leading North American Power Utility to Provide Drone-Based Services

Volatus to provide remotely piloted aircraft system (“RPAS”) inspection, mapping, and data services across 100,000 miles of transmission and distribution lines TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSXV: FLT) (OTCQB: TAKOF) (FSE: ABB.F) (“Volatus” or the “Company”), is pleased to announce that it has entered into a multi-year agreement with one of North America’s largest electricity transmission and distribution utilities. Under the agreement, Volatus has been selected to provide remotely piloted aircraft system (“RPAS”) inspection, mapping, and data services across an extensive network of approx. 100,000 miles of transmission and distribution lines. The agreement is set through August 2028, with an option for a two-year extension. Under its terms, Volatus will provide line inspections, vegetation management,...

Continue reading

Small Businesses Face Pressure as Delinquencies Remain Elevated and Uncertainty Continues in Trade Relations

– Credit stress rising in consumer-sensitive sectors and across key provinces – Equifax Canada Market Pulse — Q2 2025 Quarterly Business Credit Trends Report TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) — Canadian small businesses faced continued financial pressures in the second quarter of 2025, driven by a complex mix of macroeconomic factors and uncertain trade relations, as well as shifts in consumer and household spending, according to the latest Equifax Canada Market Pulse – Quarterly Business Credit Trends Report. Real GDP fell by 0.4 per cent, impacting the overall business outlook. The Canadian Small Business Health Index has declinedThe Canadian Small Business Health Index — a joint initiative between Equifax Canada and Business Development Bank of Canada that provides a quarterly snapshot of the health of Canadian...

Continue reading

Brunswick Corporation Makes Further Significant Gains at Cannes Boat Show

CANNES, France, Sept. 16, 2025 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC), the world’s leading marine technology company, delivered an award-winning performance at the 2025 Cannes Boat Show, with increased year-over-year boat sales and outboard market share, and several notable industry awards. Brunswick’s performance at Cannes is an encouraging sign for the upcoming Genoa and Southampton boat shows this week. Brunswick reported nearly double the total number of boats sold vs. the 2024 Show for its premium brands at the Show: Navan; Boston Whaler; and Sea Ray, suggesting continued strong consumer demand in the luxury and performance segments. Mercury Marine delivered another strong performance at Cannes, increasing its overall share of outboards boats on display year-over-year by five points to 66%. Growth was fueled by...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.